A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

NCT05929079 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing the medication retatrutide in adults with type 2 diabetes who also have obesity or overweight to see how it affects their body weight.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 1,000 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2023-07 · est. completion 2026-05

Where 98 sites · Argentina, Australia, Brazil, India, Mexico, Romania, Spain, United States

What this study is testing ClinicalTrials.gov NCT05929079 ↗

Description as written by the study sponsor.

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.

Treatments tested

Retatrutide also known as LY3437943 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Percent Change from Baseline in Body Weight
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
GLP-1 drugs	retatrutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05929079 ↗